REVIEW OF DISEASE BURDEN OF LUNG CANCER IN CHINA'S BEIJING AND SHANGHAI
Author(s)
HU C1, Huang L2, Zhao D2, Xu L2
1Astrazeneca(China), Beijing, China, 2Astrazeneca (China), Beijing, China
Presentation Documents
OBJECTIVES: Lung cancer has now become NO.1 disease of all cancers in both incidence and mortality in China. Since lung cancer imposes great disease and economic burden on patients in China, lots of studies have investigated national status of disease burden of lung cancer. However, few studies pay attention to disease burden of lung cancer in China’s super big cities, such as Beijing &Shanghai. Our study aims to review lung cancer’s burden in Beijing and Shanghai to inform policy making. METHODS: A comprehensive literature review of disease burden of lung cancer in Beijing Shanghai was conducted. “CNKI” and “Wanfang data”, the biggest databases for Chinese journals, were searched through to Dec. 31th, 2014. RESULTS: In 2010, incidence and mortality of lung cancer in China are 46.08/10and 37.00/10CONCLUSIONS: Lung cancer has made Chinese patients incur great loss in both DALYs and money, which is a conspicuous reminder to policy makers to pay more attention to management of the raging disease. And early prevention and screening of lung cancer should be priorities to slow increasing speed of disease burden.
Conference/Value in Health Info
2015-05, ISPOR 2015, Philadelphia, PA, USA
Value in Health, Vol. 18, No. 3 (May 2015)
Code
PCN56
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Oncology